Guest Blogs
-
Novel Approaches To Treating Depression
5/4/2022
Suicide is the second leading cause of death among Americans between the ages of 10 and 34, per the Centers for Disease Control and Prevention (CDC). That alarming statistic is enough to classify suicide as a major public health concern, even with the ubiquity of anti-depression drugs in today’s pharmaceutical market.
-
Results May Disappoint, But Don’t Throw In The Tau On Treatments For Alzheimer’s Disease
5/4/2022
Alzheimer’s disease (AD) is an irreversible degeneration of the brain and the most common form of dementia. Globally, more than 50 million people are living with AD, and without a medical intervention those rates could more than triple by 2050.
-
Gene Deserts May Hold An Oasis — A Cure For HIV
4/19/2022
In this blog, learn how the HIV virus hides hides its DNA in remote stretches of the human genome known as “gene deserts.”
-
How Can Guidelines Keep Pace With Science? “Living Evidence” May Help
4/4/2022
The “living-evidence” model where research findings are continuously updated as new research becomes available is recommended. Learn why this approach can result in the much faster release of updated guidelines —especially in areas where the amount of new research has skyrocketed.
-
New Draft FDA Guidance On ADC Pharmacology
4/4/2022
Read to find out more about the new guidelines on ADC pharmacology, as well as what the guidelines mean for research organizations and drug companies.
-
Lilly/Entos Deal Reinforces The Significance Of Delivery Mechanisms For Nucleic Acid-Based Therapies
4/4/2022
As part of a research partnership aimed at improving the delivery of nucleic acid-based therapies targeting nervous system diseases, American pharmaceutical company Eli Lilly and Company (Lilly) has secured exclusive rights to Canada-based Entos Pharmaceuticals’ Fusogenix delivery technology.
-
New AstraZeneca Drug For HER2-Low Breast Cancer Aces Phase III Trial
4/4/2022
Drug manufacturer AstraZeneca has aced a Phase III trial for its new drug, Enhertu, which seeks to treat breast cancer cases classified as “HER2-low.” Read on to find out more about this exciting new drug prospect.
-
Cancer Cure? 10-Year Leukemia Remission Reported With Personalized T-Cell Therapy
3/2/2022
Learn more about how chimeric antigen receptor (CAR) T-cell therapy, which uses engineered T-cells to target cancer, held leukemia at bay in two patients for at least 10 years.
-
A New Proteo-Genomic Map Shows How Genes Connect To A Variety Of Diseases
3/2/2022
Learn how a recently published proteo-genomic map uncovers hundreds of novel connections between human diseases.
-
Collaborations Continue To Reveal The Potential Of Understanding Protein Structure And Interactions
2/3/2022
Proteins are a string of amino acids linked together in a specific sequence, with 20 possible amino acids coming into play. Learn how this makes them dynamic, coming together and apart to send signals, change cell states, fight infections, reproduce, and even create new proteins.